GlobeNewswire Inc | May 27, 2021 07:00AM EDT

May 27, 2021

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences:

Jefferies Healthcare Conference (June 1 ? 4, 2021)Speaker: Dr. Alon Seri-Levy, Chief Executive OfficerDate: Tuesday, June 1, 2021Time: 8:30 ? 8:55 am EDT Raymond James Human Health Innovation Conference(June 21 ? 23, 2021)Speaker: Dr. Alon Seri-Levy, Chief Executive OfficerDate: Tuesday, June 22, 2021Time: 10:00 ? 10:30 am EDT

A recording of the webcast of each presentation will be available in the Investors/Events & Presentations section of the Companys website at www.sol-gel.com.

About Sol-Gel Technologies

Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of TWYNEO, under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visitwww.sol-gel.com.

For further information, please contact:

Sol-Gel Technologies

Gilad MamlokChief Financial Officer+972-8-9313433

Investor relationsIrina KofflerLifeSci Advisors+1-917-734-7387ikoffler@lifesciadvisors.com